Skip to main content
. 2022 Jan 28;4(1):e210070. doi: 10.1148/rycan.210070

Figure 2:

Structures of rucaparib, 18F fluorthanatrace (18F-FTT) and 125I KX-1. Fluoroethyl and iodo moieties were added to rucaparib scaffold to enable radiofluorination and radioiodination. Both radioactive analogs exhibit high binding affinities toward PARP-1. The PET radiotracer, 18F-FTT, was used for the preclinical and clinical imaging studies, while 125I KX-1 (18F-FTT analog) was used for PET tracer evaluation. FDA = Food and Drug Administration, PARPi = poly (adenosine diphosphate–ribose) polymerase inhibitor.

Structures of rucaparib, 18F fluorthanatrace (18F-FTT) and 125I KX-1. Fluoroethyl and iodo moieties were added to rucaparib scaffold to enable radiofluorination and radioiodination. Both radioactive analogs exhibit high binding affinities toward PARP-1. The PET radiotracer, 18F-FTT, was used for the preclinical and clinical imaging studies, while 125I KX-1 (18F-FTT analog) was used for PET tracer evaluation. FDA = Food and Drug Administration, PARPi = poly (adenosine diphosphate–ribose) polymerase inhibitor.